Selegiline in Treatment of Cocaine Dependence - 2 - Full Text View

Selegiline in Treatment of Cocaine Dependence - 2

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000188

Purpose

The purpose of this study is to assess selegiline as a pharmacotherapy for cocaine dependence.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Selegiline	Phase II

Drug Information available for:

Selegiline 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Selegiline hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Selegiline in Treatment of Cocaine Dependence

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Estimated Enrollment:	0
Study Start Date:	September 1994

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000188

Locations


United States, Pennsylvania
	PDVAMC Treatment Research Center
	Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators


Principal Investigator:	James Cornish, M.D.	University of Pennsylvania

More Information

Study ID Numbers:	NIDA-00144-2, K20-00144-2
First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000188
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders

Selegiline

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Cocaine

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action

Anti-Dyskinesia Agents

Therapeutic Uses

Physiological Effects of Drugs

Monoamine Oxidase Inhibitors

Antiparkinson Agents

Enzyme Inhibitors

Central Nervous System Agents

Protective Agents

Neuroprotective Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on December 03, 2008